| Fund Name | Location |
| Bigcolors | China, Hong Kong, Hong Kong Island |
| Bluegrass Growth Fund Partners | New York, New York, United States |
| codecentric AG | Düsseldorf, Germany, Nordrhein-Westfalen |
| Communicade | New York, New York, United States |
| CRYSTAL VENTURES | - |
| eHUB | Alberta, Canada, Edmonton |
| Exact Sciences | Madison, United States, Wisconsin |
| Fitz Gate Ventures | Houston, Texas, United States |
| JettyCove | - |
| Rewired | Lausanne, Switzerland, Vaud |
| Rice Management Company | - |
| Selr8r | Birmingham, England, United Kingdom |
| Staidson Hongkong Investment | China, Hong Kong, Hong Kong Island |
| Symantec Ventures | - |
| TechFund Capital | France, Ile-de-France, Paris |
| the Entrepreneur Fund. | - |
| Transworld Group | - |
| Vertex Pharmaceuticals | Boston, Massachusetts, United States |
| Visionplus | Finland, Helsinki, Southern Finland |
| Will Hunting Capital | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
BioNTech | $325M | 09 Jul 2019 | Mainz, Rheinland-Pfalz, Germany |
– haemaLogiX from Sydney is a biotech company developing a drug to treat a rare blood disorder.
– The company raised $10M in Series A funding.
– The round was led by Platinum Asset Management via its Platinum International Health Care Fund.
– The investment will be used to support the manufacturing of the next batch of the Kappa antibody plus the conduct of a higher dose, 30mg/kg, monotherapy study and prepare for two further studies.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
BioNTech | $325M | 09 Jul 2019 | Mainz, Rheinland-Pfalz, Germany |
